Related Experiment Video

Updated: Jun 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Anticoagulation prescription in atrial fibrillation

Vicente Bertomeu-González1, Alberto Cordero, Pilar Mazón

  • 1Cardiology Department, Hospital Universitario de San Juan, Carretera nacional N-332, sn. 03550, Alicante, Spain. vbertog@gmail.com

Expert Opinion on Pharmacotherapy
|June 4, 2011
PubMed

Insights

Factors influencing anticoagulant prescription in atrial fibrillation (AF) patients are linked to bleeding risk and immediate thrombotic risk, not just long-term risk. Current arrhythmia and lack of antiplatelet use strongly predict anticoagulation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Atrial fibrillation (AF) significantly increases stroke risk.
  • Anticoagulation is crucial for managing AF-related thrombotic events.
  • Understanding prescription patterns is vital for optimizing patient care.

Purpose of the Study:

  • To identify factors associated with anticoagulant prescription in AF patients.
  • To analyze the influence of risk scores (CHADS(2), CHA(2)DS(2)-VASc, HAS-BLED) on treatment decisions.
  • To explore the relationship between immediate clinical factors and antithrombotic therapy.

Main Methods:

  • Retrospective analysis of 1524 AF patients from outpatient clinics.
  • Calculation of CHADS(2), CHA(2)DS(2)-VASc, and HAS-BLED scores for all patients.
  • Univariable and multivariable logistic regression models to identify predictors of anticoagulant prescription.

Main Results:

  • 62% of patients received anticoagulation, 37% received antiplatelet therapy.
  • Higher CHADS(2) and CHA(2)DS(2)-VASc scores correlated with increased anticoagulation rates.
  • Presence of arrhythmia (OR 33) and absence of antiplatelet treatment (OR 0.17) were strongly associated with anticoagulation.

Conclusions:

  • Antithrombotic therapy prescription in AF is influenced by perceived bleeding risk and immediate thrombotic risk.
  • Clinical factors like current arrhythmia and concurrent antiplatelet use play a significant role.
  • Long-term thrombotic risk, while important for prognosis, may be less immediate in driving prescription decisions.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...